Supreme Court Pauses Ban on Mail-Order Abortion Pill Mifepristone
Supreme Court mifepristone mail ban stay May 2026
In a critical intervention for reproductive healthcare access, the United States Supreme Court issued an administrative stay on Monday, May 4, 2026, temporarily blocking a lower court’s decision that would have banned the distribution of the abortion pill mifepristone by mail.
Justice Samuel Alito, who oversees emergency requests from the Fifth Circuit, issued the order to provide the High Court with additional time to review the rapidly escalating legal battle. The stay effectively pauses a Friday ruling from the U.S. Court of Appeals for the Fifth Circuit, which had sought to reinstate outdated in-person dispensing requirements and block a 2023 Food and Drug Administration (FDA) policy allowing the drug to be prescribed via telehealth and delivered by mail.
According to official reports from Bloomberg Law, the administrative stay is currently set to expire on May 11, 2026, unless the Court takes further action.
The legal standoff began on May 1, when a three-judge panel of the Fifth Circuit granted a request from the state of Louisiana to halt the mailing of the drug, which is used in more than 60% of all abortions in the United States.
The appellate court argued that the FDA’s decision to relax prescribing rules “injects upheaval” into state laws and that the agency had failed to adequately address safety concerns raised by Republican attorneys general. In response, Danco Laboratories and GenBioPro, the primary manufacturers of the drug, filed emergency appeals to the Supreme Court on Saturday, warning that the sudden reinstatement of in-person requirements would create “regulatory and administrative chaos” nationwide.
As reported by The Guardian, Danco argued that forcing patients to navigate unnecessary barriers would disrupt time-sensitive medical decisions for millions of Americans, even in states where abortion remains legal.
The Biden-Trump transition has complicated the federal government’s stance on the issue, as the FDA is currently undergoing a “comprehensive safety review” of mifepristone protocols that was initiated last year.
While the Trump administration has previously suggested it would wait for the review to conclude before altering regulations, the Fifth Circuit’s decision sought to bypass that process. Attorney General Letitia James of New York, leading a coalition of 21 states, filed an amicus brief on Monday urging the Supreme Court to maintain the status quo, arguing that the rollback is not supported by science and interferes with states’ rights to protect healthcare access.
As the May 11 deadline approaches, the nation’s highest court faces its most significant abortion-related decision since the 2024 challenge to the drug was dismissed on standing grounds, with the future of medication abortion hanging in the balance.
